Astellas Pharma (FRA:YPHA) Cyclically Adjusted Revenue per Share: €4.63 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:YPHA Astellas Pharma Inc FRA:YPHA
81 GF Score
Price €12.50
GF Value €11.91
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Astellas Pharma Cyclically Adjusted Revenue per Share?

Astellas Pharma FRA:YPHA -0.79% 81 Cyclically Adjusted Revenue per Share is €4.63 as of Jun. 2026. GuruFocus rates FRA:YPHA with a GF Score™ of 81/100 and a GF Value™ of €11.91 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Astellas Pharma's adjusted revenue per share for the three months ended in Jun. 2026 was €1.926. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €4.63 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Astellas Pharma's average Cyclically Adjusted Revenue Growth Rate was 8.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Astellas Pharma was 8.70% per year. The lowest was 4.80% per year. And the median was 6.10% per year.

As of today (2026-09-03), Astellas Pharma's current stock price is €12.50. Astellas Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €4.63. Astellas Pharma's Cyclically Adjusted PS Ratio of today is 2.70.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Astellas Pharma was 3.80. The lowest was 1.57. And the median was 2.85.


Astellas Pharma  (FRA:YPHA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Astellas Pharma's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=12.50/4.63
=2.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Astellas Pharma was 3.80. The lowest was 1.57. And the median was 2.85.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Astellas Pharma Cyclically Adjusted Revenue per Share Related Terms


Astellas Pharma Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Astellas Pharma's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astellas Pharma Cyclically Adjusted Revenue per Share Chart

Astellas Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.58 4.63 4.40 4.87 4.61

Astellas Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.68 4.63 4.54 4.61 4.63

FRA:YPHA vs LLY, JNJ, ABBV: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Astellas Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Cyclically Adjusted PS Ratio falls into.


FRA:YPHA
81GF Score
Astellas Pharma Inc FRA:YPHA
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Astellas Pharma Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Astellas Pharma's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.926/113.6000*113.6000
=1.926

Current CPI (Jun. 2026) = 113.6000.

Astellas Pharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.292 98.000 1.498
201612 1.371 98.400 1.583
201703 1.217 98.100 1.409
201706 1.252 98.500 1.444
201709 1.174 98.800 1.350
201712 1.333 99.400 1.523
201803 1.152 99.200 1.319
201806 1.297 99.200 1.485
201809 1.256 99.900 1.428
201812 1.458 99.700 1.661
201903 1.261 99.700 1.437
201906 1.450 99.800 1.651
201909 1.415 100.100 1.606
201912 1.486 100.500 1.680
202003 1.412 100.300 1.599
202006 1.363 99.900 1.550
202009 1.335 99.900 1.518
202012 1.387 99.300 1.587
202103 1.284 99.900 1.460
202106 1.326 99.500 1.514
202109 1.355 100.100 1.538
202112 1.429 100.100 1.622
202203 1.264 101.100 1.420
202206 1.477 101.800 1.648
202209 1.471 103.100 1.621
202212 1.544 104.100 1.685
202303 1.355 104.400 1.474
202306 1.361 105.200 1.470
202309 1.380 106.200 1.476
202312 1.492 106.800 1.587
202403 1.415 107.200 1.499
202406 1.551 108.200 1.628
202409 1.622 108.900 1.692
202412 1.795 110.700 1.842
202503 1.586 111.100 1.622
202506 1.691 111.700 1.720
202509 1.682 112.000 1.706
202512 1.741 113.000 1.750
202603 1.632 112.700 1.645
202606 1.926 113.600 1.926

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €4.63 mean?
Astellas Pharma (FRA:YPHA) has a Cyclically Adjusted Revenue per Share of €4.63 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Astellas Pharma and its competitors.
Is Astellas Pharma's Cyclically Adjusted Revenue per Share too high?
Astellas Pharma's current Cyclically Adjusted Revenue per Share is €4.63. Overall, Astellas Pharma has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Cyclically Adjusted Revenue per Share compare to LLY and JNJ?
Astellas Pharma's Cyclically Adjusted Revenue per Share of €4.63 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Astellas Pharma and its competitors. Astellas Pharma's current Cyclically Adjusted Revenue per Share is €4.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (FRA:YPHA) is currently considered Fairly Valued. The stock's GF Value™ is €11.91, compared to a current price of €12.50 — trading 5% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €4.63. Astellas Pharma's overall GF Score™ is 81/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Astellas Pharma (FRA:YPHA), the current Cyclically Adjusted Revenue per Share is €4.63 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astellas Pharma (FRA:YPHA) Overvalued in 2026?

Based on GuruFocus' analysis, Astellas Pharma stock appears to be overvalued. The current stock price of €12.50 is trading 5% above its estimated GF Value™ of €11.91. GuruFocus considers Astellas Pharma to be Fairly Valued.

Key valuation signals for FRA:YPHA:

  • Cyclically Adjusted Revenue per Share: €4.63
  • GF Value™: €11.91 vs. price of €12.50 (5% above fair value)
  • GF Score™: 81/100 with 5 warning signs

No single metric tells the full story. See the FRA:YPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Astellas Pharma Business Description

Address 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
81GF Score

Get the complete analysis for FRA:YPHA

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.50
Price
€11.91
GF Value